Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: The use of ibrutinib has changed the management and clinical history of patients with multiple-treated chronic lymphocytic leukemia (CLL). Nevertheless, an increasing number of patients develop resistance to treatment, with mechanisms still to be fully clarified. Since HSP70 plays a...

Descripción completa

Detalles Bibliográficos
Autores principales: Frezzato, Federica, Visentin, Andrea, Severin, Filippo, Pizzo, Serena, Ruggeri, Edoardo, Mouawad, Nayla, Martinello, Leonardo, Pagnin, Elisa, Trimarco, Valentina, Tonini, Alessia, Carraro, Samuela, Pravato, Stefano, Imbergamo, Silvia, Manni, Sabrina, Piazza, Francesco, Brunati, Anna Maria, Facco, Monica, Trentin, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582437/
https://www.ncbi.nlm.nih.gov/pubmed/34771616
http://dx.doi.org/10.3390/cancers13215453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582437/
https://www.ncbi.nlm.nih.gov/pubmed/34771616
http://dx.doi.org/10.3390/cancers13215453

Ejemplares similares